Retatrutide, also known as LY3437943, is a glucagon-like peptide 1 agonist; what separates this peptide from the others is it also targets gastric inhibitory polypeptide receptor (GIPR) and glucagon receptors (GCGR), making it a triagonist.
In the lab settings, Retatrutide mimics the natural glucagon and glucose production within the hepatocytes, while inducing lipolysis in the adipocytes.
References
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O’Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. PMID: 35985340.
Camille Lupianez‐Merly, Saam Dilmaghani, Kia Vosoughi, Michael Camilleri, Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks, Alimentary Pharmacology & TherapeuticsAlimentary Pharmacology & TherapeuticsAlimentary Pharmacology & Therapeutics, 10.1111/apt.17856, 59, 4, (475-491), (2024).
Our support team is at your service, ensuring customer satisfaction.
